Loading
Microbial Therapeutics / Disease Diagnosis / Crispr-cas Systems · Journal article
Synthetic and Systems Biotechnology · June 6, 2026
A consensus or society position rather than new primary data.
This review synthesizes synthetic biology strategies for engineering bacteria in disease diagnosis and therapy, highlighting applications such as living biosensors, targeted drug delivery, and immunotherapy. The authors emphasize persistent translational challenges including stable in vivo colonization, immunogenicity control, large-scale production standardization, and regulatory framework development.
Journal article.
Recombinant human insulin produced using Escherichia coli was FDA approved in 1982, demonstrating therapeutic potential of engineered microbes i-ROBOT engineered bacterium integrates three modules (fluorescent reporting, base editing, drug secretion) to diagnose, record, and treat inflammatory bowel disease Synthetic probiotic producing lactate activates HIF-1α-NDUFA4L2 signaling in dendritic cells to suppress CNS autoimmune responses
No quantitative efficacy or safety data reported for the technologies and examples discussed
Clinicians should recognize engineered bacteria as an emerging platform for diagnostics and therapeutics, though translation remains constrained by colonization stability, immunogenicity, manufacturing, and regulatory gaps. The field illustrates synthetic biology's potential to address limitations of conventional therapeutic approaches through programmable microbial functions.
This is a narrative review article synthesizing engineering strategies for bacterial therapeutics without presenting original empirical data or meta-analyzed outcomes.
Quoted from the source exactly as published.
Clinicians should recognize engineered bacteria as an emerging platform for diagnostics and therapeutics, though translation remains constrained by colonization stability, immunogenicity, manufacturing, and regulatory gaps. The field illustrates synthetic biology's potential to address limitations of conventional therapeutic approaches through programmable microbial functions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Synthetic biology is an interdisciplinary field that integrates knowledge and techniques from modern biology and many other disciplines to design and construct novel biological systems or to modify existing life forms. Its core technologies include gene editing (e.g., CRISPR/Cas9), DNA assembly, in vivo directed evolution, and integration with artificial intelligence. The development of these technologies has greatly advanced the application of synthetic biology in medicine. In disease diagnosis, engineered bacteria have shown considerable promise. They can be designed to sense disease-specific signals and produce detectable reporter outputs, thereby establishing new paradigms for early diagnosis and real-time disease monitoring. For example, bacteria engineered via synthetic biology have been developed as "living sensors" to detect disease biomarkers. In therapeutic applications, synthetic biology offers a fresh perspective on using microorganisms to treat diseases. Researchers can design and construct microorganisms with tailored functions for targeted drug delivery, immunotherapy, and microbiome modulation. These applications not only improve the precision and efficacy of treatments but also offer innovative solutions to overcome the limitations of conventional therapeutic approaches. However, despite their considerable potential, the clinical translation of engineered bacteria still faces numerous challenges, such as ensuring stable in vivo colonization, controlling immunogenicity, standardizing large-scale production, and establishing robust regulatory and ethical frameworks. This review summarizes engineering strategies aimed at enhancing the safety and efficacy of bacterial therapies, with the goal of optimizing bacterial functions and expanding their potential in diagnostics and precision medicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.